Tirzepatide Acetate 2023788-19-2 Free Base: Technical Overview & Research Guidelines

Definition and Chemical Identity of CAS 2023788-19-2

Tirzepatide acetate (CAS 2023788-19-2) is a synthetic 39-amino-acid peptide designed as a dual agonist for the GIP and GLP-1 receptors. Structurally modified with a C20 fatty diacid diacyl moiety, it exhibits prolonged half-life characteristics in preclinical models. It is supplied exclusively as a high-purity lyophilized research peptide for in vitro assay systems and non-human experimental research.

In chemical databases, CAS number 2023788-19-2 specifically designates the linear peptide sequence corresponding to tirzepatide, often isolated or reconstituted in its acetate salt form or free base state during solid-phase peptide synthesis (SPPS). Understanding the nuances between the free base peptide mass and its counter-ion salt formulations is critical for quantitative analytical assays, bio-layer interferometry, and cell culture binding studies. Researchers utilizing tirzepatide research compounds must account for precise peptide content calculations to maintain reproducible molar concentrations across experimental trials.

Molecular Structure and Modifications

The primary sequence of tirzepatide is derived from the native human GIP sequence, incorporated with strategic amino acid substitutions to optimize dual-receptor affinity and metabolic stability. The polypeptide chain incorporates two non-coded amino acid residues, alpha-aminobutyric acid (Aib), at positions 2 and 13. These Aib insertions confer structural resistance against enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), a primary peptidase responsible for rapid inactivation of native incretin peptides.

Crucially, the peptide chain is conjugated at the Lysine residue at position 20 via a specialized linker—consisting of a gamma-glutamate (gamma-Glu) linker attached to two 2-(2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units—bound to a C20 fatty diacid chain. This lipophilic C20 diacid modification enables reversible binding to albumin, significantly retarding renal clearance and enhancing physiological persistence in animal models. The molecular formula for the un-complexed peptide is C225H348N48O68, possessing a theoretical monoisotopic molecular weight of approximately 4813.45 Da.

Mechanism of Action: Dual GIP and GLP-1 Receptor Agonism

Unlike selective single-receptor agonists, tirzepatide functions as an engineered 'twincretin' that simultaneously recruits signaling cascades through both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Pharmacodynamic studies in recombinant cell lines demonstrate that tirzepatide exhibits balanced affinity for the GIP receptor comparable to native GIP, while possessing approximately five-fold lower potency for the GLP-1 receptor relative to native GLP-1. This targeted ratio drives distinct intracellular cyclic adenosine monophosphate (cAMP) signaling outputs.

In vitro functional assays reveal that dual activation alters downstream receptor trafficking and beta-arrestin recruitment. While native GLP-1 causes robust beta-arrestin-2 recruitment leading to receptor endocytosis and desensitization, tirzepatide displays biased agonism at the GLP-1R, favoring cAMP generation over beta-arrestin recruitment. Preclinical studies suggest that this biased signaling profile minimizes receptor internalisation, preserving surface receptor availability and maintaining sustained signal transduction over extended incubation windows. Researchers exploring broad metabolic pathways can reference our comprehensive collection of GIP and GLP-1 dual agonists to compare secondary messenger activity.

Preclinical Literature Review: Metabolic and Cellular Research Findings

Preclinical investigations utilizing rodent models (e.g., db/db mice, diet-induced obesity (DIO) Sprague-Dawley rats) demonstrate that dual GIP/GLP-1 activation produces synergistic metabolic effects distinct from monotherapy targeting either receptor alone. In vitro islet perfusion models indicate that tirzepatide stimulates glucose-dependent insulin secretion from pancreatic beta cells with greater efficacy than equimolar selective GLP-1 agonists.

Furthermore, preclinical research highlights profound effects on lipid metabolism and hepatic gene expression. In cultured primary hepatocytes and DIO animal models, tirzepatide administration was associated with upregulation of genes involved in fatty acid beta-oxidation and downregulation of lipogenic transcripts. Central nervous system receptor mapping in rodent models suggests that dual activation in the hypothalamus and hindbrain suppresses appetite signaling pathways more effectively than isolated GLP-1 stimulation. To explore related literature on metabolic regulation, visit the main PX1 peptide research library.

Comparative Analysis: Dual and Tri-Agonist Class Interactions

To establish context within incretin mimetic research, tirzepatide must be evaluated alongside mono-agonist and tri-agonist compounds. Selective single-target agonists, such as semaglutide peptide, engage only the GLP-1 receptor, relying entirely on GLP-1 pathway transduction for glucose regulation and anorectic central signaling. While semaglutide demonstrates high potency at the GLP-1R, it lacks the GIP-mediated glucagon-modulating and adipose-tissue-sensitizing effects provided by dual agonists.

Conversely, next-generation multi-agonists expand this signaling capacity even further. Compounds such as retatrutide peptide incorporate triple agonism across the GIP, GLP-1, and glucagon (GCGR) receptors. In comparative preclinical bioassays, retatrutide demonstrates enhanced energy expenditure dynamics due to glucagon receptor engagement, whereas tirzepatide focuses strictly on the interplay between GIP and GLP-1 pathways. Researchers can browse the complete PX1 research peptide catalog to select specific receptor affinity profiles for comparative in vitro studies.

Peptide Synthesis, Purification, and Counter-Ion Dynamics

The production of tirzepatide acetate (CAS 2023788-19-2) requires advanced Solid-Phase Peptide Synthesis (SPPS) using Fmoc chemistry, followed by specialized fragment condensation or automated step-wise assembly to accommodate the complex C20 fatty acid side chain. Following cleavage from the resin matrix, the crude peptide contains truncated sequences, deletion peptides, and organic counter-ions.

Purification is performed via multi-step preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). During the final ion-exchange and descaling steps, the peptide is routinely converted into its acetate salt form ($CH_3COO^-$) to maximize solubility, stability, and compatibility with biological cell cultures. Free base preparations require rigorous pH neutralization and precise salt-content determination (acetate mass percentage) via ion chromatography to ensure accurate effective peptide mass delivery in precise biochemical assays.

Analytical Quality Control: COA, HPLC, MS, and Endotoxin Verification

For laboratory researchers, rigorous analytical validation is required to ensure experimental reproducibility and eliminate confounding variable artifacts caused by synthesis contaminants or bacterial endotoxins. PX1 Research subjects every production lot of tirzepatide acetate to a stringent battery of analytical tests conducted by independent ISO 17025 accredited testing facilities.

Key quality specifications verified on every Certificate of Analysis (COA) include:

• Chemical Purity Verification: Determined via analytical RP-HPLC. PX1 Research guarantees a minimum purity threshold of >98% (typically exceeding 99%), ensuring minimal presence of failure sequences or diastereomers.

• Mass Identity Confirmation: Measured using Liquid Chromatography-Mass Spectrometry (LC-MS) or Electrospray Ionization Mass Spectrometry (ESI-MS). Observed monoisotopic mass must match theoretical mass parameters precisely.

• Endotoxin Quantitation: Verified via Chromogenic Recombinant Factor C (rFC) or LAL assay methods. Endotoxin limits are strictly maintained at <0.01 EU/mg to prevent immune activation or cytotoxicity in sensitive cell cultures.

• Lot Traceability & Origin: Fully synthesized within GMP-compliant, USA-based manufacturing facilities with verified batch tracking.

Reconstitution Protocol for In Vitro Assay Systems

Proper reconstitution technique is imperative to maintain the tertiary structure and bioactivity of lyophilized tirzepatide. Because the hydrophobic C20 diacid side chain alters surface tension and solubility kinetics, adherence to standardized laboratory guidelines is essential.

For basic cell culture or enzymatic assay preparation, refer to the following procedure:

1. Equilibration: Allow the sealed peptide vial to equilibrate to room temperature (20°C to 25°C) for at least 30–45 minutes prior to reconstitution to minimize condensation inside the vial.

2. Solvent Selection: Reconstitute using sterile, preservative-free Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear vortexing.

3. Aseptic Addition: Introduce the diluent gently along the internal glass wall of the vial rather than shooting liquid directly onto the lyophilized cake.

4. Dissolution: Gently swirl the vial manually. Allow 5–10 minutes for complete dissolution into a clear, colorless solution. Do not agitate aggressively to prevent aggregation.

For detailed mathematical calculations and diluent volumes, consult the PX1 peptide reconstitution guide or utilize our institutional wholesale account portal for bulk laboratory requests.

Storage and Stability Specifications

Lyophilized tirzepatide acetate exhibits high thermal stability when stored under controlled environment conditions. Dry lyophilized powder should be stored at -20°C for short-to-medium term storage (up to 12 months) or at -80°C for long-term storage (exceeding 12 months) in a desiccated environment protected from light.

Once reconstituted into an aqueous solution, peptide stability decreases significantly due to potential hydrolytic degradation and peptide aggregation. Reconstituted stock solutions should be aliquoted into sterile micro-centrifuge tubes to prevent repeated freeze-thaw cycles and maintained at 2°C to 8°C for immediate use (within 7 to 14 days), or frozen at -80°C for up to 30 days. Avoid the use of frost-free freezers due to temperature fluctuations during automatic defrost cycles.